Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Extended coverage of HPV vaccination in middle-aged adults to prevent oropharyngeal cancers.

Arya SC, Agarwal N.

Hum Vaccin Immunother. 2012 Jul;8(7):959. doi: 10.4161/hv.20043. Epub 2012 Jul 1. No abstract available.

PMID:
22777098
2.

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

Goldstone SE, Vuocolo S.

Expert Rev Vaccines. 2012 Apr;11(4):395-406. doi: 10.1586/erv.12.20. Review.

PMID:
22551023
3.

Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?

Osazuwa-Peters N.

Vaccine. 2013 Nov 12;31(47):5500-5. doi: 10.1016/j.vaccine.2013.09.031. Epub 2013 Oct 3. Review.

PMID:
24095883
4.

Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination.

Gillison ML.

J Adolesc Health. 2008 Oct;43(4 Suppl):S52-60. doi: 10.1016/j.jadohealth.2008.07.002. Review.

5.

[The disease burden of human papillomavirus in men is substantial and can potentially be prevented].

Kiellberg Larsen H, Kofoed K, Sand C.

Ugeskr Laeger. 2013 Feb 4;175(6):349-53. Review. Danish.

PMID:
23402241
6.

HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?

Takes RP, Wierzbicka M, D'Souza G, Jackowska J, Silver CE, Rodrigo JP, Dikkers FG, Olsen KD, Rinaldo A, Brakenhoff RH, Ferlito A.

Oral Oncol. 2015 Dec;51(12):1057-60. doi: 10.1016/j.oraloncology.2015.10.011. Epub 2015 Oct 29. Review.

PMID:
26520047
7.

Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?

Isaranuwatchai W, Graham DM, Siu LL, Hoch JS.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):763-5. doi: 10.1586/14737167.2014.946012. Epub 2014 Aug 6. Review.

PMID:
25095728
8.

Indications for the HPV vaccine in adolescents: a review of the literature.

Soares GR, Vieira Rda R, Pellizzer EP, Miyahara GI.

J Infect Public Health. 2015 Mar-Apr;8(2):105-16. doi: 10.1016/j.jiph.2014.08.011. Epub 2014 Oct 13. Review.

9.

[Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention].

Acs N, Bata Z, Danko D, Hernádi Z, Kálmán M, Kornya L, Kovács J, Mézáros G, Molnár MP, Mór Z, Novák Z, Sobel G, Szentirmay Z, Takács L, Tisza T.

Orv Hetil. 2012 Dec;153 Suppl:3-38. Review. Hungarian. No abstract available.

PMID:
23687666
10.

Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.

Poljak M.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6. Review.

11.

Human papillomavirus (HPV): making the case for 'Immunisation for All'.

Prue G, Lawler M, Baker P, Warnakulasuriya S.

Oral Dis. 2017 Sep;23(6):726-730. doi: 10.1111/odi.12562. Epub 2016 Aug 29. Review.

PMID:
27492979
12.

Prophylactic human papillomavirus vaccines: past, present and future.

Anderson LA.

Pathology. 2012 Jan;44(1):1-6. doi: 10.1097/PAT.0b013e32834d7bd8. Review.

PMID:
22157686
13.

An overview on the implementation of HPV vaccination in Europe.

Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, Panatto D, Gasparini R, Boccalini S.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:128-35. Epub 2011 Jan 1. Review.

PMID:
21245659
14.

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

Dunne EF, Datta SD, E Markowitz L.

Cancer. 2008 Nov 15;113(10 Suppl):2995-3003. doi: 10.1002/cncr.23763. Review.

15.

[HPV vaccination].

Stronski Huwiler S, Spaar A.

Ther Umsch. 2016;73(5):241-6. doi: 10.1024/0040-5930/a000786. Review. German.

PMID:
27268446
16.

Human papillomavirus in head and neck cancer.

Palma DA, Nichols AC.

CMAJ. 2014 Mar 18;186(5):370. doi: 10.1503/cmaj.130849. Epub 2013 Dec 2. Review. No abstract available.

17.

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.

Gertig DM, Brotherton JM, Saville M.

Sex Health. 2011 Jun;8(2):171-8. doi: 10.1071/SH10001. Review.

PMID:
21592430
18.

HPV vaccination in Italy: perspectives after 1-year experience.

Icardi G.

J Prev Med Hyg. 2008 Dec;49(4):125-8. Review. No abstract available.

PMID:
19350958
19.

Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.

Monsonego J, Cortes J, Greppe C, Hampl M, Joura E, Singer A.

Vaccine. 2010 Nov 29;28(51):8065-72. doi: 10.1016/j.vaccine.2010.10.017. Epub 2010 Nov 16. Review.

PMID:
20971114
20.

Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus.

Bärnighausen T, Bloom DE, Cafiero ET, O'Brien JC.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:70-6. doi: 10.1111/j.1469-0691.2012.03977.x. Epub 2012 Aug 6. Review.

Supplemental Content

Support Center